title: Impact of a unified CT angiography system on outcome of patients with hepatocellular carcinoma.
abstract: OBJECTIVE
  The purpose of our study was to evaluate the impact of a unified CT angiography (CTA) system for the management of patients with hepatocellular carcinoma (HCC).
  
  
  METHODS
  A total of 1,312 patients with HCC who had been diagnosed and treated between 1990 and 2003 were studied. The clinical characteristics and survival rate were compared between patients who underwent pretreatment evaluation of tumor progression by a unified CTA system and those who underwent evaluation by a conventional angiography system. In addition, the survival rates for 438 patients who underwent transcatheter arterial chemoembolization (TACE) as initial treatment were compared between patients who were treated using a unified CTA system and those who were treated without the system.
  
  
  RESULTS
  Overall, the survival rate was higher in patients who underwent pretreatment examination using a unified CTA system than in those who underwent examination without it (p < 0.0001). The survival rate was higher when focusing on patients with HCC of stage I (p = 0.0093). In patients who underwent TACE as an initial treatment, the survival rate was higher in patients treated by TACE using a unified CTA system than in those without it (p = 0.0023).
  
  
  CONCLUSIONS
  The more accurate and detailed pretreatment evaluation of HCC progression using a unified CTA system contributed to the improvement of survival of patients with HCC. In addition, it contributed to the improved efficacy of TACE with an increased survival rate.
authors.affiliation: Department of Gastroenterology, Ogaki Municipal Hospital, 4-86 Minaminokawa, Ogaki, Gifu 503-8502, Japan.
authors.forename: Hidenori
authors.initials: H
authors.lastname: Toyoda
authors.forename: Takashi
authors.initials: T
authors.lastname: Kumada
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Sone
mesh_terms: D000368:Aged; D000792:Angiography / Q000379:methods*; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging* / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D016009:Chi-Square Distribution; D018450:Disease Progression; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D018709:Statistics, Nonparametric; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome